A clinical study of cancer peptides vaccine therapy in the patients who have recieved surgical resection and had no residual tumor for head and neck cancer
Phase 1
Recruiting
- Conditions
- head and neck cancer
- Registration Number
- JPRN-UMIN000008380
- Lead Sponsor
- Department of Oral and Maxillofacial surgery, Graduated school of medicine Kumamoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. Pregnancy or lactation. 2. Patients who are treated with steroid or immunotherapy during clinical trial. 3. Patients have uncontrollable associated cancer. 4. Patients who are not agree. 5. Patients who are inappropriate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safty
- Secondary Outcome Measures
Name Time Method immunological response and clinical efficacy
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cancer peptides vaccine therapy in head and neck cancer patients post-surgery?
How does adjuvant cancer peptides vaccine therapy compare to standard-of-care treatments for head and neck cancer recurrence prevention?
Which biomarkers are associated with response to cancer peptides vaccine therapy in head and neck cancer patients?
What are the known adverse events of cancer peptides vaccine therapy in head and neck cancer patients and how are they managed?
Are there combination approaches or competitor drugs that enhance the efficacy of cancer peptides vaccine therapy in head and neck cancer?